Anita Andreano1,2, Paola Rebora3, Maria Grazia Valsecchi3, Antonio Giampiero Russo4. 1. Center of Biostatistics for Clinical Epidemiology, School of Medicine and Surgery, University of Milan Bicocca, Via Cadore 48, 20900, Monza, Italy. anita.andreano@unimib.it. 2. Epidemiology Unit, Agency for Health Protection of the Province of Milan, Milan, Italy. anita.andreano@unimib.it. 3. Center of Biostatistics for Clinical Epidemiology, School of Medicine and Surgery, University of Milan Bicocca, Via Cadore 48, 20900, Monza, Italy. 4. Epidemiology Unit, Agency for Health Protection of the Province of Milan, Milan, Italy.
Abstract
PURPOSE: There is a lack of real-world studies evaluating the impact on survival of an evidence-based pathway of care in breast cancer. The aim of this work is to investigate the effect of adherence to guidelines on long-term survival for a cohort of Italian breast cancer patients. METHODS: The cohort included incident female breast cancer cases (2007-12), from the registry of the Milan province (Italy), not metastatic at diagnosis and receiving primary surgery. We selected sets of indicators, according to patient and tumor characteristics. We then defined the pathway of care as adherent to guidelines if it fulfilled at least 80% of the indicators. Indicators were measured using different administrative health databases linked on a unique key. A causal inference approach was used, drawing a directed acyclic graph and fitting an inverse probability weighted marginal structural model, accounting for patient's demographic, socioeconomic and tumor characteristics. RESULTS: The analysis included 6333 patients, 69% of them were classified as having an adherent care. Mean age was 61 years (standard deviation, 13.6 years) and half of the patients were in Stage I (50%) at diagnosis. Median follow-up time was 5.6 years. Overall, 5-year survival was 90% (95% CI, 89-91%). The estimated risk of death was 30% lower for patients with adherent than nonadherent care (hazard ratio [HR], 0.66; 95% CI, 0.55-0.77). CONCLUSIONS: Our study confirms, in real-world care, the impact on survival of receiving a care pathway adherent to guidelines in non-metastatic breast cancer patients.
PURPOSE: There is a lack of real-world studies evaluating the impact on survival of an evidence-based pathway of care in breast cancer. The aim of this work is to investigate the effect of adherence to guidelines on long-term survival for a cohort of Italian breast cancerpatients. METHODS: The cohort included incident female breast cancer cases (2007-12), from the registry of the Milan province (Italy), not metastatic at diagnosis and receiving primary surgery. We selected sets of indicators, according to patient and tumor characteristics. We then defined the pathway of care as adherent to guidelines if it fulfilled at least 80% of the indicators. Indicators were measured using different administrative health databases linked on a unique key. A causal inference approach was used, drawing a directed acyclic graph and fitting an inverse probability weighted marginal structural model, accounting for patient's demographic, socioeconomic and tumor characteristics. RESULTS: The analysis included 6333 patients, 69% of them were classified as having an adherent care. Mean age was 61 years (standard deviation, 13.6 years) and half of the patients were in Stage I (50%) at diagnosis. Median follow-up time was 5.6 years. Overall, 5-year survival was 90% (95% CI, 89-91%). The estimated risk of death was 30% lower for patients with adherent than nonadherent care (hazard ratio [HR], 0.66; 95% CI, 0.55-0.77). CONCLUSIONS: Our study confirms, in real-world care, the impact on survival of receiving a care pathway adherent to guidelines in non-metastatic breast cancerpatients.
Entities:
Keywords:
Adherence to guidelines; Administrative health databases; Breast cancer care; Causal inference; Process indicators; Survival
Authors: Marcus Jannes; Alexander König; Martin Kolben; Claudius Fridrich; Verena Kirn Journal: Breast Care (Basel) Date: 2022-01-14 Impact factor: 2.268
Authors: Ena Niño de Guzmán; Yang Song; Pablo Alonso-Coello; Carlos Canelo-Aybar; Luciana Neamtiu; Elena Parmelli; Javier Pérez-Bracchiglione; Montserrat Rabassa; David Rigau; Zuleika Saz Parkinson; Iván Solà; Adrián Vásquez-Mejía; Ignacio Ricci-Cabello Journal: Breast Cancer Res Treat Date: 2020-05-06 Impact factor: 4.872
Authors: Ignacio Ricci-Cabello; Adrián Vásquez-Mejía; Carlos Canelo-Aybar; Ena Niño de Guzman; Javier Pérez-Bracchiglione; Montserrat Rabassa; David Rigau; Ivan Solà; Yang Song; Luciana Neamtiu; Elena Parmelli; Zuleika Saz-Parkinson; Pablo Alonso-Coello Journal: BMC Health Serv Res Date: 2020-10-07 Impact factor: 2.655